The Pharmaceutical Industry From January To February 2010 Data Analysis: Steadily - Medical -

Q1 2010: market performance: the pharmaceutical sector performance outperform

, Shen 10 000 A mean decrease of 1.8%, 7.3% higher medical section, the overall valuation of 30.6 times the plate, at a reasonable range. Plate 34 lines a second-line stocks outperformed stocks, hot relative dispersion. fundamentals: the Pharmaceutical Industry January-February 2010, revenues increased 28.3%, in consumer goods in the forefront, but a cyclical industry, the low base effect in 2009, lower than the overall industry revenue growth of 39.7%; as pharmaceutical manufacturing Industry profit growth 45.7%, lower than the overall industrial profits grew 119.7%. January-February 2010 revenue and profit growth in pharmaceutical manufacturing data show a smooth trend, the overall fourth quarter of 2009 continued the trend of high growth, and statistics reflect the healthy operation of the pharmaceutical industry, with over Drugs Tender Completion of medical reform will continue to promote the demand for expansion. Molecular industry see: Chemistry API Revenues and profits continued to grow, 10 January-February 2009 from the total profit growth surged 14% to 63%, in this regard and the low base last year, the more is mainly due to the economic rebound, demand has picked up; Chemicals drug income growth, gross margin compared to 2009 increased by about 2 percentage points, making pre-tax profit margin by approximately 1 percentage point, profit growth speed up; Herbal Pieces Revenue growth accelerated, pre-tax profit margin remained stable compared to last year's fourth quarter profit growth slowed slightly; proprietary Chinese medicines from January to February revenue growth remained steady, profit chain to enhance the growth rate 14.9 percentage points; bio-pharmaceutical taxes down 2 percentage points before the profit margin profit growth compared to last year, down sharply from September to November.

Medical reform bill by the United States, long-term positive Generic And medical equipment export business: the core of U.S. medical reform is to increase health care coverage (the U.S. medical equipment and prescription drugs on demand so there will be nearly 20% increase), lower medical expenses (increased low-cost procurement and promotion of generic drugs generic drugs into the patent), which may bring some U.S. patent drugs business impact, while China, India and other developing countries Pharmaceutical Industry Will welcome the opportunity because of cost advantages. We recommend that exports to the U.S. concern has been the sea is medicine, Huahaiyaoye, diving medicine, Wandong, Shandong Pharmaceutical Glass, and very likely future exports HRH medicine, Yang Pu medical.

We believe that industry leaders to accelerate growth throughout the year there will be a good absolute returns: the industry leading tilt policy to the industry, large enterprises accelerate growth, and gradually win situation is already clear. We believe that industry leaders to accelerate growth throughout the year there will be a good absolute return, the core recommended combination: HRH medicine Yunnanbaiyao East E-Jiao, Hualan material, Sinopharm shares Kehua Bio. Molecular industry see:? ? Chinese medicine: Essential drugs system Implemented smoothly, exclusive varieties of basic tender price has not declined, promising an exclusive variety of essential medicines and regional leader. Recommended Yunnanbaiyao, East E-Jiao, Jiang Chinese medicine, the daughter of medicine, CRC 39.

Chemical Pharmaceutical: along the main line of the international transfer of generic drugs, continue to be optimistic HRH medicine, the sea is medicine, Huahaiyaoye. In addition, the bullish Humanwell Technology, Hainan Hai drugs, the letter established Thai, Double-Crane Pharmaceutical and other individual species.

Biopharmaceuticals: shortage of blood products, vaccines, sub-sectors to benefit from state investment increased, diagnostic reagents, 20% revenue growth sub-sectors, the blood screening market to look forward to, recommend Hualan objects Kehua Biology, Shanghai RAAS.

Pharmaceutical business: Sinopharm shares and the same medicine, compared with Sinopharm undervalued, Sinopharm system integration concern. SW Securities Co., Ltd.

by: gaga

POST COMMENT

Irritable Bowel Syndrome - Prescription Drugs And Treatment For Ibs More People Dying From Drug Abuse Origins Rehab Center - Arizona Drug Rehab & Arizona Alcohol Rehab What can a Medical Call Answering Service Do for You? Medical Malpractice Cases How To Deter Against Ever Increasing Medical Errors! Military Lawyers Virginia Alexandria Drug Distribution Court Martial Army Armed Forces Modafinil Drug Information Do You Think Alcohol And Drugs Are Fun? The Three Ws To Recovery From Drug Addiction. Duane Reade Drug Store Is Not Better Than Santa Claus! Application of LED in medical field Abzan ( Sitz bath) A Regime in Unani System of Medicine Knowing More About Medical Transcriptionist